CAMBRIDGE, Mass.–(BUSINESS WIRE)– Seres Therapeutics, Inc. (Nasdaq: MCRB) (âSeresâ or the âCompanyâ), a leading microbiome therapeutics company, today announced that on April 5, 2023, the Compensation and Talent Committee of Seresâ board of directors granted inducement equity grants covering an aggregate of 22,000 shares of its common stock to three… Read More
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
